Ibutamoren mk (MK-677) is a non-peptide growth hormone secretagogue that acts as a ghrelin receptor agonist, stimulating endogenous growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. The compound has been investigated in research settings for its potential involvement in anabolic signalling pathways, including those associated with protein synthesis and nitrogen balance.

Preliminary human studies have reported changes in fat-free mass and specific body composition markers, though these findings are limited and require further validation. Ibutamoren powder is supplied as a research-grade ingredient for use in experimental formulations, including encapsulated and powdered delivery systems.

What is Ibutamoren?

Ibutamoren mk (MK-677), also known as ibutamoren mesylate, is a synthetic ghrelin receptor agonist designed to stimulate endogenous growth hormone (GH) secretion through oral administration. The compound selectively binds to the growth hormone secretagogue receptor 1a (GHSR-1a) in the hypothalamus, initiating pulsatile GH release and downstream elevation of insulin-like growth factor 1 (IGF-1). Research-grade ibutamoren powder is typically synthesized under process controls aimed at achieving a purity of≥98%, normally presenting as a white to off-white crystalline solid with favorable oral bioavailability and pharmacokinetic characteristics.

High-purity ibutamoren powder is manufactured in GMP-compliant facilities with full batch traceability, rigorous impurity profiling, and validated analytical methods. The compound has been reported to exhibit stable characteristics under typical storage conditions in research environments and organoleptically neutral properties, making ibutamoren mk well-suited for integration into encapsulated, tableted, and powdered delivery formats. With an elimination half-life of approximately 24 hours, MK-677 has been administered once daily in investigational protocols, providing formulators with a practical option for research applications that explore anabolic signaling, body composition endpoints, and metabolic parameters.

Specification Sheet Reference:

作用メカニズム

Ibutamoren mk (MK-677) functions as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a) located in the pituitary gland and hypothalamus, triggering pulsatile growth hormone (GH) secretion and subsequent elevation of circulating insulin-like growth factor 1 (IGF-1). Some studies suggest this mechanism may operate with reduced interference from endogenous GH feedback loops, though its long-term effects on physiological pulsatility remain under investigation. The compound exhibits ghrelin-receptor agonist activity similar to that of endogenous ghrelin, the endogenous ligand associated with fasting-induced GH release, thereby engaging anabolic signalling cascades linked to protein synthesis, nitrogen balance, and cellular proliferation in skeletal muscle tissue.

Preliminary preclinical models and limited human trials have reported increases in markers of bone turnover and fat-free mass, effects hypothesised to involve IGF-1–related pathways. Additional investigational findings with MK-677 include modulation of sleep architecture parameters and exploratory observations on substrate utilisation, though these outcomes remain subject to further validation. The compound's influence on insulin sensitivity and glucose homeostasis has been noted in early-phase studies of ibutamoren, warranting continued research to characterize long-term metabolic dynamics and dose-dependent response profiles in controlled settings.

Ibutamoren Benefits

Increased Lean Mass

Preliminary human trials administering ibutamoren mk at 25 mg daily have reported increases of 1–2 kg in fat-free mass over 8–12 week periods in subjects participating in structured resistance training protocols. These ibutamoren benefits remain limited in scope and reflect outcomes in small, controlled cohorts requiring replication in larger populations.

Improved Sleep Quality

Investigational studies have documented changes in slow-wave sleep duration and sleep stage distribution in subjects receiving MK-677, parameters of interest in research exploring recovery physiology and neuroendocrine regulation. The mechanistic basis for these ibutamoren benefits is under continued evaluation.

Nitrogen Retention Support

Ibutamoren mk has been studied for its effects on nitrogen retention and whole-body protein kinetics, with preliminary data indicating shifts toward positive nitrogen balance in experimental settings. These mechanistic effects are of interest in research exploring protein metabolism and body composition models, representing key benefits for research applications.

GH/IGF-1 Elevation

Some clinical pharmacology studies have reported increases in growth hormone pulse amplitude and IGF-1 concentrations following ibutamoren MK administration; however, study sizes were limited, and the findings require confirmation. These endocrine responses form the mechanistic foundation for ongoing research into anabolic signaling pathways and downstream metabolic endpoints, highlighting the core benefits of ibutamoren in investigational settings.

Safety and Potential Side Effects of Ibutamoren

Short-term human studies administering ibutamoren MK at 25 mg daily for 8–12 weeks reported generally tolerable effects, including mild appetite stimulation, transient fluid retention, and peripheral oedema. These observations were based on small cohorts and should be interpreted with caution. Changes in fasting glucose and insulin concentrations were noted in some participants, consistent with growth hormone's known counter-regulatory effects on glucose metabolism.

Extended preclinical toxicology studies in rodents have not revealed carcinogenic signals at high experimental doses, although the relevance to humans remains unverified. Limited clinical data have not reported serious adverse cardiovascular or hepatic events, but long-term safety has not been established. As with any investigational compound, ibutamoren powder is intended for research use under controlled conditions with appropriate monitoring and is not recommended for individuals with pre-existing metabolic or cardiovascular conditions, except in supervised research studies.

Regulatory and FDA Status

Ibutamoren MK-677 is recognised as a research-grade investigational compound, offering unique opportunities for scientific exploration in growth hormone and IGF-1 modulation. While it has not received FDA approval for therapeutic or dietary supplement use and does not hold GRAS or DEA status, researchers can utilise ibutamoren MK in controlled experimental studies under appropriate regulatory frameworks. Compliance with DSHEA requirements, including New Dietary Ingredient (NDI) notification where applicable, ensures the lawful use of ingredients in research-focused projects.

In the European Union, MK-677 is designated for investigational applications under the Novel Food and Medicinal Product regulations, and similar research-oriented provisions exist in Australia, Canada, and other regions. Suppliers of ibutamoren powder provide comprehensive documentation, including certificates of analysis and traceability records, which support the responsible and compliant use of this compound in scientific studies.

Comparison with Other Recovery Ingredients

Ibutamoren MK-677 is being studied as a research ingredient for potential applications in body composition, recovery physiology, and anabolic signaling, although evidence remains limited. Unlike phosphocreatine donors or leucine metabolites that target localised metabolic pathways, ibutamoren MK acts as a growth hormone secretagogue, modulating GH and IGF-1 levels in investigational research settings.

The table below compares ibutamoren mk with other commonly studied ingredients in experimental recovery formulations, highlighting differences in primary mechanism, functional research targets, formulation compatibility, and reported investigational outcomes. This comparative framework helps formulators select complementary or alternative ingredients based on mechanistic alignment, delivery format constraints, and research objectives within controlled study designs.

In-Depth Comparison: Ibutamoren MK-677 vs Creatine Monohydrate

Ibutamoren mk (MK-677) and creatine monohydrate represent mechanistically distinct research ingredients. Ibutamoren mk functions as a growth hormone secretagogue, modulating endogenous GH and IGF-1 to influence systemic anabolic signalling, while creatine enhances intramuscular phosphocreatine stores for ATP regeneration during high-intensity activity. Preliminary small-scale human studies report 1–2 kg increases in fat-free mass over 8 weeks with ibutamoren MK; these changes are attributed to hormonal effects, but evidence is limited and requires further research. Creatine studies document similar 1–3 kg gains, linked to cellular hydration and phosphocreatine saturation.

Ibutamoren mk's extended half-life supports once-daily dosing, though appetite stimulation has been observed. Creatine typically employs loading phases to optimise tissue saturation. Investigational research has explored sleep architecture and nitrogen balance with MK-677, complementing the characterised effects of creatine on strength metrics. Experimental combinations of ibutamoren MK (25 mg) and creatine (5 g) are being explored in controlled research settings, with potential additive effects under investigation.

Synergistic Combinations

Ibutamoren MK-677 + Creatine Monohydrate

• Mechanistic rationale: Ibutamoren mk modulates GH/IGF-1 signaling pathways while creatine enhances phosphocreatine-mediated ATP regeneration.
• Research interest: Investigational endpoints include fat-free mass and strength parameters in resistance training models.
• Formulation application: Commonly designed at 25 mg ibutamoren powder + 5 g creatine in daily encapsulated formats.

Ibutamoren MK-677 + Beta-Alanine

• Mechanistic rationale: GH secretagogue activity of MK-677 paired with carnosine-mediated intramuscular pH buffering.
• Research interest: Exploratory studies on endurance metrics and fatigue resistance in high-volume exercise protocols.
• Formulation application: Integrated into pre-workout powdered blends; paresthesia response from beta-alanine noted.

Ibutamoren MK-677 + HMB

• Mechanistic rationale: Anabolic signaling enhancement via GH/IGF-1 from ibutamoren mk combined with leucine metabolite effects on protein degradation pathways.
• Research interest: Investigated nitrogen retention and lean tissue preservation during caloric restriction models.
• Formulation application: Targeted for body composition research with ibutamoren powder in encapsulated delivery systems.

Ibutamoren MK-677 + Turkesterone

• Mechanistic rationale: Growth hormone secretagogue MK-677 paired with phytoecdysteroid-mediated effects on protein synthesis pathways.
• Research interest: Preliminary evaluation of additive anabolic signaling in experimental models with ibutamoren mk.
• Formulation application: Emerging in plant-based anabolic ingredient combinations for investigational use.

Ibutamoren MK-677 + L-Theanine

• Mechanistic rationale: Endocrine modulation from ibutamoren mk combined with GABAergic activity and neurotransmitter regulation.
• Research interest: Sleep architecture parameters and recovery physiology in post-exercise contexts.
• Formulation application: Designed for evening administration with ibutamoren powder in recovery-focused encapsulated products.

Market Outlook and Development Prospects

Research interest in orally bioavailable growth hormone secretagogues, including ibutamoren MK-677, continues to grow robustly in investigational sectors across North America and Europe, underpinned by increasing demand from academic laboratories, biotech companies, and contract research organisations conducting mechanistic and translational studies. The global growth hormone secretagogue receptor‑1 market is projected to expand significantly, with reports estimating a CAGR of ~12.5% to 2033 for synthetic secretagogues, including MK-type compounds.

On the supply side, ibutamoren benefits from a stable manufacturing pipeline. Its non-peptide structure enables relatively cost-efficient synthetic routes, and established contract manufacturers in the research chemical market are scaling up production to meet the growing demand for high-purity (≥98%) batches. This helps ensure availability and batch-to-batch consistency for research-scale buyers.

From a pricing perspective, although public data for MK-677 as a research raw material is limited, the broader trend in peptide and synthetic hormone research chemicals suggests moderate pricing volatility. The pharmaceutical chemicals market is forecast to continue growing (e.g., a projected CAGR of ~5–6% for speciality chemical ingredients), which supports continued downward pressure on large-scale synthesis costs.

Meanwhile, end-user demand is being driven by an increasing number of preclinical and translational R&D projects exploring GH/IGF-1 modulation, aging biology, muscle recovery, and metabolic health. Researchers are also investigating synergistic regimens that combine MK-677 with other investigational compounds (e.g., creatine, beta-alanine), further expanding the potential use cases and purchase drivers.

Regulatory clarity remains a limiting factor for commercial nutrition-grade or therapeutic use; however, for research use, suppliers are responding with well-documented, traceable products. COAs, GMP-like quality controls, and batch traceability are increasingly becoming standard to support institutional procurement. This compliance infrastructure lowers risk for research institutions and improves reproducibility.

Looking ahead, the sustained interest in ghrelin-receptor agonists, coupled with the firm foundation of raw-material manufacturing, positions ibutamoren MK-677 as a strategically important research ingredient. As more academic and biotech labs invest in secretagogue research — especially in Europe and North America — demand for MK-677 as a high-purity, research-grade input is likely to remain strong.

Frequently Asked Questions (FAQ)

Q1. What purity is standard for ibutamoren powder?

Research-grade ibutamoren powder is typically supplied at a purity of≥98% with HPLC characterization and certificates of analysis; however, traceability may vary depending on the supplier.

Q2. Does ibutamoren mk increase appetite?

Clinical observations have documented moderate increases in appetite in subjects receiving ibutamoren mk, an effect consistent with ghrelin receptor agonism and growth hormone's known orexigenic properties. Study protocols may incorporate meal timing strategies to manage this response with MK-677.

Q3. How long does MK-677 take to work?

Pharmacodynamic markers of GH secretion from ibutamoren MK are detectable within the first administration cycle, while body composition endpoints, such as fat-free mass changes, are typically evaluated over 4–8 week study periods with structured assessment intervals.

Q4. Is ibutamoren MK-677 suitable for daily use?

Published investigational protocols have utilized ibutamoren MK at a dose of 25 mg once daily for 8–12 weeks, with monitoring of metabolic, endocrine, and body composition parameters in research settings.

Q5. What certifications come with commercial lots?

Research-grade ibutamoren powder is supplied with GMP manufacturing documentation, third-party analytical verification, certificates of analysis including purity assays and impurity profiles, and full batch traceability records to support compliant use in experimental applications.